期刊
JOURNAL OF BIOMEDICAL SCIENCE
卷 29, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s12929-022-00790-6
关键词
LRG1; Inflammation; Immunity; Neovascularization; Vascular normalization; Fibrosis; Cancer; Diabetes; Endothelial cell; Neutrophils
资金
- Wellcome Trust [206413/B/17/Z]
- British Heart Foundation [PG/16/50/32182]
- Diabetes UK [18/0005856]
- Rosetrees Trust
- UCL POC fund
- UCL Technology Fund
- National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust
- UCL Institute of Ophthalmology
- UKRI/MRC [G1000466]
- Wellcome Trust [206413/B/17/Z] Funding Source: Wellcome Trust
- MRC [G1000466] Funding Source: UKRI
LRG1 is a secreted glycoprotein that plays an important role in multiple human conditions, including cancer, diabetes, cardiovascular disease, neurological disease, and inflammatory disorders. While LRG1 is essentially redundant in development and homeostasis, emerging data suggest its novel role in innate immunity and tissue integrity. LRG1 is also discussed as a potential biomarker for diagnosis, prognosis, and monitoring of various conditions.
The secreted glycoprotein leucine-rich alpha-2 glycoprotein 1 (LRG1) was first described as a key player in pathogenic ocular neovascularization almost a decade ago. Since then, an increasing number of publications have reported the involvement of LRG1 in multiple human conditions including cancer, diabetes, cardiovascular disease, neurological disease, and inflammatory disorders. The purpose of this review is to provide, for the first time, a comprehensive overview of the LRG1 literature considering its role in health and disease. Although LRG1 is constitutively expressed by hepatocytes and neutrophils, Lrg1(-/-) mice show no overt phenotypic abnormality suggesting that LRG1 is essentially redundant in development and homeostasis. However, emerging data are challenging this view by suggesting a novel role for LRG1 in innate immunity and preservation of tissue integrity. While our understanding of beneficial LRG1 functions in physiology remains limited, a consistent body of evidence shows that, in response to various inflammatory stimuli, LRG1 expression is induced and directly contributes to disease pathogenesis. Its potential role as a biomarker for the diagnosis, prognosis and monitoring of multiple conditions is widely discussed while dissecting the mechanisms underlying LRG1 pathogenic functions. Emphasis is given to the role that LRG1 plays as a vasculopathic factor where it disrupts the cellular interactions normally required for the formation and maintenance of mature vessels, thereby indirectly contributing to the establishment of a highly hypoxic and immunosuppressive microenvironment. In addition, LRG1 has also been reported to affect other cell types (including epithelial, immune, mesenchymal and cancer cells) mostly by modulating the TGF beta signalling pathway in a context-dependent manner. Crucially, animal studies have shown that LRG1 inhibition, through gene deletion or a function-blocking antibody, is sufficient to attenuate disease progression. In view of this, and taking into consideration its role as an upstream modifier of TGF beta signalling, LRG1 is suggested as a potentially important therapeutic target. While further investigations are needed to fill gaps in our current understanding of LRG1 function, the studies reviewed here confirm LRG1 as a pleiotropic and pathogenic signalling molecule providing a strong rationale for its use in the clinic as a biomarker and therapeutic target.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据